

## Queries for Author



Journal: BMJ Open

Paper: bmjopen-2015-010790

Title: Factors influencing women's attitudes towards antenatal vaccines, group B *Streptococcus* and clinical trial participation in pregnancy: an online survey

The proof of your manuscript appears on the following page(s).

It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs.

Please read the proofs carefully, checking for accuracy, verifying the reference order and checking figures and tables. When reviewing your page proof please keep in mind that a professional copyeditor edited your manuscript to comply with the style requirements of the journal.

**This is not an opportunity to alter, amend or revise your paper; it is intended to be for correction purposes only.** The journal reserves the right to charge for excessive author alterations or for changes requested after the proofing stage has concluded.

During the preparation of your manuscript for publication, the questions listed below have arisen (the query number can also be found in the gutter close to the text it refers to). Please attend to these matters and return the answers to these questions when you return your corrections.

**Please note, we will not be able to proceed with your article if these queries have not been addressed.**

**A second proof is not normally provided.**

Note Reference	Note
N1	IMPORTANT: Corrections at this stage should be limited to those that are essential. Extensive corrections will delay the time to publication and may also have to be approved by the Editor. <b>Alterations cannot be made after the article has published online.</b>
N2	Author SURNAMEs (family names) have been highlighted - please check that these are correct. Please check all names are spelt correctly, and that affiliations and correspondence details are accurate.
N3	Please check funding statement is accurate (and include grant numbers if applicable).
N4	Your article should display in PubMed Central within 2–3 weeks of publication.

Query Reference	Query
Q1	Please ensure your article is compliant with your funder's open access policy and the correct license is applied (see <a href="http://bmj.co/OALicences">http://bmj.co/OALicences</a> ).
Q2	If your article is linked to a clinical trial please provide the trial registration number and the stage it relates to - Post-results, Pre-results or Results.
Q3	Please provide complete publication details for references [4, 8 and 10].
Q4	Please provide the citation for [*] in Table [2].

## Author query sheet

If you are happy with the proof as it stands, please email to confirm this. Minor changes that do not require a copy of the proof can be sent by email (please be as specific as possible).

Email: **production.bmjopen@bmj.com**

If you have any changes that cannot be described easily in an email, please mark them clearly on the proof using the annotation tools and email this by reply to the eProof email.

We will keep a copy of any correspondence from you related to the author proof for six months. After six months, correspondence will be deleted.

Please respond within 48 hours

# BMJ Open Factors influencing women's attitudes towards antenatal vaccines, group B *Streptococcus* and clinical trial participation in pregnancy: an online survey

Fiona McQuaid,<sup>1</sup> Christine Jones,<sup>2</sup> Zoe Stevens,<sup>1</sup> Jane Plumb,<sup>3</sup> Rhona Hughes,<sup>4</sup> Helen Bedford,<sup>5</sup> Merryn Voysey,<sup>6</sup> Paul T Heath,<sup>7</sup> Matthew D Snape<sup>1</sup>

**To cite:** McQuaid F, Jones C, Stevens Z, *et al.* Factors influencing women's attitudes towards antenatal vaccines, group B *Streptococcus* and clinical trial participation in pregnancy: an online survey. *BMJ Open* 2016;**6**:e010790. doi:10.1136/bmjopen-2015-010790

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2015-010790>).

Received 8 December 2015  
Revised 10 February 2016  
Accepted 23 March 2016



For numbered affiliations see end of article.

## Correspondence to

Fiona McQuaid;  
Fiona.mcquaid@ed.ac.uk

## ABSTRACT

**Objectives:** To explore factors influencing the likelihood of antenatal vaccine acceptance of both routine UK antenatal vaccines (influenza and pertussis) and a hypothetical group B *Streptococcus* (GBS) vaccine in order to improve understanding of how to optimise antenatal immunisation acceptance, both in routine use and clinical trials.

**Setting:** An online survey distributed to women of childbearing age in the UK.

**Participants:** 1013 women aged 18–44 years in England, Scotland and Wales.

**Methods:** Data from an online survey conducted to gauge the attitudes of 1013 women of childbearing age in England, Scotland and Wales to antenatal vaccination against GBS were further analysed to determine the influence of socioeconomic status, parity and age on attitudes to GBS immunisation, using attitudes to influenza and pertussis vaccines as reference immunisations. Factors influencing likelihood of participation in a hypothetical GBS vaccine trial were also assessed.

**Results:** Women with children were more likely to know about each of the 3 conditions surveyed (GBS: 45% vs 26%, pertussis: 79% vs 63%, influenza: 66% vs 54%), to accept vaccination (GBS: 77% vs 65%, pertussis: 79% vs 70%, influenza: 78% vs 68%) and to consider taking part in vaccine trials (37% vs 27% for a hypothetical GBS vaccine tested in 500 pregnant women). For GBS, giving information about the condition significantly increased the number of respondents who reported that they would be likely to receive the vaccine. Health professionals were the most important reported source of information.

**Conclusions:** Increasing awareness about GBS, along with other key strategies, would be required to optimise the uptake of a routine vaccine, with a specific focus on informing women without previous children. More research specifically focusing on acceptability in pregnant women is required and, given the value attached to input from healthcare professionals, this group should be included in future studies.

## Strengths and limitations of this study

- This is a large-scale study reporting the responses of over a thousand women of childbearing age in the UK.
- A wide range of clinically important questions were included regarding both current antenatal vaccines and potential clinical trials which will be of relevance to practitioners and researchers in the UK and worldwide.
- A relatively small proportion of women (2%) were actually pregnant at the time of the study and data on the women's ethnicity were not collected.
- Though an online survey enables a large number of participants to be included, it is limiting in terms of the depth of information that can be gathered. However, it can provide a useful preliminary study to a more in-depth investigation using qualitative methods.

## INTRODUCTION

Group B *Streptococcus* (GBS) is the most common cause of sepsis and meningitis in infants up to the age of 3 months with a significant morbidity and mortality.<sup>1 2</sup> Current prevention strategies (using intrapartum antibiotics) are aimed only at early onset group B strep infections (occurring in the first week of life) and there are a number of challenges in their application in developed and developing countries.<sup>3</sup> Antenatal vaccination is therefore an attractive prospect, and the clinical trial of a candidate group B strep vaccine is currently in phase II development.

Despite the promise of antenatal immunisation against group B strep, it is important to be mindful that uptake rates for existing antenatal vaccines are relatively low. In England, antenatal influenza immunisation

uptake was 44.1% in 2014/2015,<sup>4</sup> despite clear benefits for the mother and child.<sup>5</sup> Similarly, although antenatal immunisation against neonatal pertussis has an effectiveness of 91%<sup>6</sup> and has been shown to be safe,<sup>7</sup> uptake rates in the UK are currently at 56.4%, a contributing factor to the continuing tragedy of infant deaths from this illness.<sup>8</sup> It is therefore evident that simply the availability of a safe and effective antenatal vaccine does not guarantee that it will be accepted by pregnant women, and it is important to consider the relevance of this for antenatal group B strep immunisation.

This paper presents further analysis of a previously published online survey,<sup>9</sup> in which we reported that 72% of British women of childbearing age described themselves as 'likely' to receive a (hypothetical) antenatal vaccine against group B strep, a figure that increased to 82% when further information about invasive group B strep disease was provided. Presented here is a detailed analysis of the relative differences in attitudes across subgroups of age, disease knowledge and parental status to determine factors associated with increased likelihood of vaccine acceptance or refusal.

## METHODS

An online survey assessed awareness, perceptions of seriousness and acceptability of antenatal vaccines for three conditions: 'whooping cough (also called pertussis) in newborn babies', 'influenza in women while pregnant' and 'GBS (group B strep) infection in newborn babies'. Preferred sources of advice about antenatal vaccination were also investigated. The full survey questions and response categories are included in table 1. For the question 'How serious do you think the following conditions are?', a non-infectious condition, 'Heavy bleeding in pregnancy' was used as a comparison as it was assumed that the majority of women would consider this a serious condition. A five-level Likert scale was used for all questions with the exception of one free-text answer.

A link to the survey was emailed to a nationally representative sample of 1221 women aged between 18 and 44 years in England, Scotland and Wales by a market research company (ComRes, London, 13–17 September 2013). These women had previously agreed to receive emails from ComRes with surveys on a range of topics including health, politics and social issues. Participation was voluntary and no personal identifying information was collected. Owing to the nature of this survey, formal ethical approval was not required.

Demographic details were also collected including age, social class, region and whether or not the respondent had any children or was planning to have more children. No personal identifying information was collected. Respondents were assigned a social class based on their reported occupation according to the Market Research Society guidelines.<sup>10</sup> Social classes were defined according to the National Readership Survey classifications (available from [\[and-classification-data/social-grade/\]\(http://www.nrs.co.uk/nrs-print/lifestyle-and-classification-data/social-grade/\)\) and ranged from A to E, with A defined as being the highest social class and E the lowest. Weighting adjustments were applied to ensure a nationally representative sample.](http://www.nrs.co.uk/nrs-print/lifestyle-</a></p>
</div>
<div data-bbox=)

Statistical comparisons between groups were carried out using  $\chi^2$  tests, Fisher's exact test or  $\chi^2$  test for trend using a software package (Graphpad prism V.6). For clarity of presentation in the tables, answers to questions 2, 3, 4, 5, 7 and 8 were collapsed into 'don't know what it is', 'know what it is' and 'have been directly affected' for question 2; 'serious', 'not serious' and 'don't know' for question 3; 'likely', 'unlikely' and 'don't know' for questions 4, 5 and 7; and 'important', 'not important' and 'don't know' for question 8. Where significant differences were found between subcategories, for example, 'never heard of it' and 'heard of it but don't know what it is' in question 2, these are indicated in the text. The full breakdown of answers is publicly available at <http://www.comres.co.uk/poll/1028/gbs-vaccination-survey.htm>. Free-text responses to the question, 'Why would you be willing/unwilling to have a group B strep vaccine in pregnancy?' were analysed for recurrent themes and grouped accordingly, for example, 'to protect my baby's health' or 'do not like/believe in vaccines'.

Quality control measures used to ensure that respondents were paying due attention included a series of logic checks such as matching date of birth with age band and asking participants to identify shapes and colours.

## RESULTS

Of the 1221 women surveyed, 1013 returned usable answers (83%). Of those who did not, 138 (11%) did not complete the survey, 13 (1%) did not meet the inclusion criteria (eg, incorrect age or gender), 12 (1%) completed the survey after the recruitment target had been reached and 43 (4%) were discounted as they failed quality control. The proportions of respondents with and without children are shown in figure 1 and the numbers in each age category in table 2. Twenty-five per cent of the respondents were in social classes A and B (higher and intermediate managerial/professional), 29% in C1 (supervisory, clerical and junior managerial/professional), 17% in C2 (skilled manual) and 29% in DE (semiskilled, unskilled and unemployed). These social class percentages are similar to that of the 2011 household census for England and Wales.<sup>11</sup>

### Factors influencing awareness and attitudes to pertussis, influenza and group B strep

Though similar proportions of respondents had been directly affected by each of the conditions (pertussis 5%, influenza 3% and group B strep 4%), less was known about group B strep compared with pertussis or influenza ('never heard of'—pertussis: 6%; influenza: 14%;

**Table 1** Survey questions and possible responses

Question	Possible responses
1. Which one of the following statements best describes your current situation?	a. I have one or more children and don't plan to have any more. b. I have one or more children and plan to have more. c. I am/my partner is currently pregnant. d. I don't have any children now, but hope to have one or more children in the future. e. I don't have any children and don't expect to in the future.
2. How familiar are you with the following conditions?	a. I have never heard of it b. I have heard of it, but I don't know what it is c. I have heard of it, and I know what it is d. I know what it is, and I have been affected by it directly
<ul style="list-style-type: none"> <li>▶ Whooping cough (also called pertussis) in newborn babies</li> <li>▶ Influenza in women while pregnant</li> </ul>	
<ul style="list-style-type: none"> <li>▶ Group B streptococcus (group B strep) infection in newborn babies</li> </ul>	
3. How serious do you think the following conditions are?	a. Very serious b. Fairly serious c. Not very serious d. Not serious at all e. Don't know
<ul style="list-style-type: none"> <li>▶ Heavy bleeding in pregnancy (for mother or newborn child)</li> <li>▶ Whooping cough (also called pertussis) in newborn babies</li> <li>▶ Influenza in women while pregnant</li> </ul>	
<ul style="list-style-type: none"> <li>▶ Group B streptococcus (group B strep) infection in newborn babies</li> </ul>	
4. How likely or unlikely would you be willing to receive the following vaccines during pregnancy?	a. Very likely b. Fairly likely c. Fairly unlikely d. Very unlikely e. Don't know
<ul style="list-style-type: none"> <li>▶ Vaccine against whooping cough (pertussis)</li> <li>▶ Vaccine against influenza</li> <li>▶ Vaccine against group B strep infection</li> </ul>	
<p>Information provided about group B strep</p> <p>Group B strep is the UK's most common cause of meningitis and life-threatening infection in newborn babies. About 20% of UK women carry group B strep bacteria without having any symptoms. Babies can be exposed at birth and afterwards from the mother and from other sources. Most will not develop infection but about 600–700 babies a year in the UK do. Currently, antibiotics can be given during labour if the mother is considered to be at high risk of having a baby with group B strep infection, but this does not prevent all infections.</p> <p>A vaccine for pregnant women to protect their babies against group B strep is being developed. This vaccine has so far been given to many adults and to a small number of pregnant women in research studies. These studies have found no evidence of harm to the women or their unborn babies and the results suggest that the vaccine could prevent most group B strep infections in babies.</p>	
5. After reading the description above, how likely or unlikely would you be willing to receive a vaccine against group B strep <i>during pregnancy</i> ?	a. Very likely b. Fairly likely c. Fairly unlikely d. Very unlikely e. Don't know
6. Could you explain why you would be likely/unlikely to be willing to receive a vaccine against group B strep <i>during pregnancy</i> ?	a. _____ b. I prefer not to say
7. Specifically, how likely or unlikely would you be willing to receive a group B strep vaccine during pregnancy in each of the following situations?	a. Very likely b. Fairly likely c. Fairly unlikely d. Very unlikely e. Don't know
<ul style="list-style-type: none"> <li>▶ As part of a research study looking at how well this vaccine protects infants against group B strep, before the vaccine is licensed (approved for routine use in pregnancy) if the vaccine had been given to 500 pregnant women without significant safety concerns</li> </ul>	
<ul style="list-style-type: none"> <li>▶ As part of a research study looking at how well this vaccine protects infants against group B strep, before the vaccine is licensed (approved for routine use in pregnancy) if the vaccine had been given to 5000 pregnant women without any significant safety concerns</li> </ul>	
<ul style="list-style-type: none"> <li>▶ If the vaccine was licensed (approved for use), but not specifically recommended for routine use by the NHS</li> <li>▶ If the vaccine was licensed and recommended for routine use by the NHS</li> </ul>	

Continued

Table 1 Continued

Question	Possible responses
8. Please indicate how important, or otherwise, you would consider the advice of each of the following in making a decision as to whether or not you would be comfortable to receive (or for your partner to receive) a group B strep vaccine <i>during pregnancy</i> .	<ul style="list-style-type: none"> <li>▶ Very important</li> <li>▶ Fairly important</li> <li>▶ Not very important</li> <li>▶ Not at all important</li> <li>▶ Don't know</li> </ul>
▶ Partner	
▶ A midwife	
▶ An obstetrician	
▶ Your GP	
▶ Written handouts provided by the NHS	
▶ Information on the internet, for example, parent forums	
▶ The media	
▶ Friends and family	
▶ Other	

GP, general practitioner; NHS, National Health Service.

group B strep: 29%,  $p < 0.0001$ ). Those with children were significantly more likely than those without to know about each condition (see table 2), as were older women compared with younger women. However, as expected, older women were also more likely to have children (percentage with children: 18–24 years: 26%, 25–34 years: 54%, 35–44 years: 74%,  $p < 0.0001$ ). There were no statistically significant differences in awareness by social class.

Older women, those with children and those with knowledge of the relevant condition were more likely to consider pertussis and group B strep to be serious; for influenza, the differences were not significant (table 2). Generally, a higher proportion of respondents rated pertussis as more serious compared with both influenza and group B strep (pertussis 88% vs influenza 82%,  $p = 0.0002$ ; pertussis 88% vs group B strep 79%,  $p < 0.0001$ ). However, of those who reported that they knew what the specific condition was or had experienced it themselves; 92% rated both pertussis and group

B strep as either very serious or fairly serious. A higher proportion of these respondents who knew about group B strep also rated it as very serious, rather than fairly serious compared with pertussis (67% vs 59%,  $p = 0.0037$ ).

### Factors influencing attitudes to immunisation and clinical trials

The likelihood of accepting antenatal vaccination for all three conditions was not affected by age (table 2) or social class (pertussis: AB 77%, C1 73%, C2 79%, DE 72%; influenza: AB 74%, C1 69%, C2 77%, DE 69%; and group B strep: AB 75%, C1 68%, C2 76%, DE 70%; all comparisons non-significant). Those who already had children or knew about the condition were significantly more likely to be willing to receive a vaccine in pregnancy (table 2). Giving information about group B strep significantly increased the likelihood of accepting an antenatal vaccine in all groups (table 3).

Eight-hundred and ninety-eight respondents commented in the free-text section about the reasons why they would or would not accept antenatal group B strep vaccination. Of those who reported that they would be likely to accept the vaccine, the most frequently expressed views were a desire 'to protect my baby/baby's health' (27%) and the vaccine being a preventive measure (15%). Forty-three respondents stated that they would need more information before making a final decision and 12 questioned the risks/safety of the vaccine. Of those who would be unwilling to have an antenatal group B strep vaccine, 24% (16/63) stated that they did not like/believe in vaccines with the next most common issue being that they required more information (19%, 13/63) or felt there was a lack of safety evidence (17%, 11/63).

A specific recommendation for use by the National Health Service (NHS), as opposed to the vaccine simply being licensed and available, significantly increased the likelihood of respondents accepting the group B strep




Figure 1 Distribution of respondents by parental status. N=1013 women aged 18–44 years.

**Table 2** Survey responses by age, parental status and previous knowledge of the condition

	18–24 years (% of n=239)	25–34 years (% of n=359)	35–44 years (% of n=415)	p Value	Children (% of n=570)	No children (% of n=443)	p Value	Know what it is (% of n†)	Don't know what it is (% of n†)	p Value
<i>How serious would you consider the following conditions?</i>										
Heavy bleeding in pregnancy										
Serious	91	94	96	0.03	96	91	0.0011			
Don't know	5	5	4		2	7				
Not serious	4	1	0	0.002	1	2	NS			
Pertussis										
Serious	82	86	94	<0.0001	92	83	<0.0001	92	79	<0.0001
Don't know	11	9	5		5	12		4	18	
Not serious	6	4	1	0.003	3	5	NS	4	3	NS
Influenza										
Serious	81	80	85	NS	85	80	NS	88	74	<0.0001
Don't know	14	12	8		8	16		5	21	
Not serious	5	8	6	NS	8	4	0.0268	7	5	NS
Group B strep										
Serious	72	75	86	<0.0001	84	72	<0.0001	92	71	<0.0001
Don't know	21	20	12		12	24		4	26	
Not serious	7	4	1	0.0014	3	4	NS	5	3	NS
<i>How likely would you be to have a vaccine for the following conditions in pregnancy?</i>										
Pertussis										
Likely	75	76	72	NS	79	70	0.0018	77	67	0.0013
Don't know	18	15	19		12	23		44	25	
Unlikely	6	9	9	NS	9	7	NS	8	8	NS
Influenza										
Likely	73	72	70	NS	75	68	0.0211	76	65	0.0002
Don't know	18	16	18		12	23		11	26	
Unlikely	9	12	12	NS	13	9	0.0437	12	9	NS
Group B strep (pre information)										
Likely	72	72	72	NS	77	65	<0.0001	79	67	<0.0001
Don't know	22	19	20		14	28		11	25	
Unlikely	6	10	8	NS	9	7	NS	10	8	NS
Group B strep (post information)										
Likely	80	81	85	NS	86	77	<0.0001	86	80	0.0217
Don't know	13	11	10		7	16		7	14	
Unlikely	6	8	5	NS	6	6	NS	7	6	NS

Answers were mutually exclusive and p values indicate differences between groups for that answer versus all other answers.

NS, non-significant, that is, p>0.05. Percentages are rounded to the nearest whole number.

\*Respondents self-defined whether they had been directly affected; therefore, this does not necessarily refer to their own children.

†Know what it is: pertussis n=727, flu n=609, group B strep n=374. Don't know what it is: n=286, flu n=404, group B strep n=639.

465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522

523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580

**Table 3** Effect of providing information about group B strep (see table 1) on likelihood of being willing to receive a group B strep vaccine in pregnancy

Group	Preinformation (%)	Postinformation (%)	p Value
18–24 years (n=239)	185 (72)	208 (80)	0.0236
25–34 years (n=359)	255 (72)	289 (81)	0.0038
35–44 years (n=415)	286 (72)	337 (85)	<0.0001
Children (n=557)	428 (77)	481 (86)	<0.0001
No children (n=456)	297 (65)	352 (77)	<0.0001
Prior knowledge (n=374)	297 (79)	321 (86)	0.0262
No prior knowledge (n=639)	429 (67)	512 (80)	<0.0001

vaccine (79% vs 52%,  $p<0.0001$ ), proportions that remained higher in those with previous knowledge about group B strep (table 4).

A smaller proportion of women were likely to receive an antenatal group B strep vaccine as part of a research study than if licensed (42% (if previously given to 5000 women) or 32% (if previously given to 500 pregnant women) vs 52% (if licensed but not routinely recommended)). In early stage development (ie, vaccine administered to fewer than 500 pregnant women), previous knowledge of group B strep increased the likelihood of respondents being willing to take part in a research study; however, it made no difference to this decision if the vaccine had been given to 5000 pregnant women (table 4). Age and social class made no difference to the proportion of women willing to take part in group B strep vaccine research, but a higher percentage of those who already had children reported that they would be likely to be willing to receive a group B strep vaccine as part of a clinical trial (table 4).

### Sources of advice

The importance to women of advice from various sources in making decisions about antenatal vaccination is shown in figure 2. General practitioners (GPs) were the source of advice rated as important by the highest proportion of respondents (87%) closely followed by midwives (84%). Twenty per cent more women felt that written NHS handouts were more important compared with internet sources such as parent forums (78% vs 58%) and half indicated that the media was not an important source of advice for them. Generally, older respondents (35–44 years) were more likely to rate advice from maternity health professionals as important than the youngest age group (midwife: 18–24 years (79%), 35–44 years (87%),  $p<0.01$ ; obstetrician: 18–24 years (69%), 35–44 years (86%),  $p<0.0001$ ), women aged 25–34 years also followed this trend (group differences were statistically significant for obstetricians but not midwives). However, younger women were more likely to rate advice from friends and family as important (18–24 years (72%), 25–34 years (64%), 35–44 years (62%),  $p<0.005$ ). There were no significant age group differences in ratings for partners, the internet or the media. Those with children rated each of the sources as more important than those without children, although

those without children were more likely to answer ‘don’t know’.

### DISCUSSION

These findings emphasise the critical importance of information about group B strep to optimise uptake of a potential antenatal vaccine, and that this may need to be specifically targeted at women in their first pregnancy. Even a brief explanation about group B strep increased the likelihood of vaccine acceptance by 7–13% and a specific national recommendation for its use significantly increased the potential uptake rate; however, it is important to combine this information with other strategies to promote uptake. Women of childbearing age rate the importance of advice from healthcare professionals, particularly their GP, very highly.

This survey forms part of a larger project funded by Meningitis Now entitled ‘Preparing the UK for an effective Group B streptococcus vaccine’, and was designed to provide preliminary information on the views of the UK population about GBS and a possible antenatal vaccine. The potential for vaccination against group B strep is particularly important as a trivalent glycoconjugate vaccine has recently been trialled in over 300 pregnant women with no vaccine-related safety concerns and large-scale clinical trials are likely to begin in the near future.<sup>12 13</sup> Universal antenatal vaccination against group B strep could have several advantages over intrapartum antibiotics. It would most likely protect against both early-onset and late-onset disease, while intrapartum antibiotics are only able to prevent early-onset infection. Concerns about antibody resistance and the practical issue of administering intravenous antibiotics at least 2 h before birth would no longer be relevant. This is particularly important as in one UK study, 81% of mothers whose babies went on to develop group B strep disease had not received adequate intrapartum antibiotics, despite having risk factors.<sup>14</sup> Primary prevention through vaccination could potentially avoid these situations; however, more information is needed on the immunogenicity and safety of the vaccine and, most importantly, whether or not it would be acceptable to pregnant women.

While it is encouraging that over 70% of respondents reported that they would be likely to have antenatal



**Table 4** Likelihood of accepting group B strep vaccine in four difference scenarios by age, parental status and previous knowledge of group B strep

How likely would you be to have a group B strep vaccine in the following situations?	18–24 years (% of n=239)	25–34 years (% of n=359)	35–44 years (% of n=415)	Children (% of n=557)	No children (% of n=456)	Know what it is (% of n=374)	Don't know what it is (% of n=639)	p Value	p Value
Licensed and recommended									
Likely	78	79	80	81	76	88	77	NS	0.0163
Don't know	15	12	14	11	16	10	16	NS	NS
Unlikely	8	9	6	7	7	7	8	NS	NS
Licensed, not specifically recommended									
Likely	56	52	50	52	52	57	49	NS	0.0132
Don't know	17	19	21	18	21	16	21	NS	NS
Unlikely	27	29	29	30	27	27	30	NS	NS
Part of a research study, previously tested in 5000 pregnant women									
Likely	50	44	38	46	40	47	41	0.0139	NS
Don't know	19	15	21	16	21	16	20	NS	NS
Unlikely	31	40	41	38	38	38	38	0.0247	0.0246
Research study, previously tested in 500 pregnant women									
Likely	34	35	28	37	27	36	30	NS	0.0009
Don't know	21	17	24	19	23	18	23	NS	NS
Unlikely	45	48	47	44	50	46	47	NS	NS

Answers were mutually exclusive and p values indicate differences between groups for that answer versus all other answers. NS, non-significant, that is,  $p > 0.05$ .


vaccinations against the three conditions surveyed, in reality vaccine uptake is much lower. The peak uptake for antenatal pertussis vaccine in England was 61.5% in November 2013 and has since fallen,<sup>8 15</sup> despite guidelines that it should be routinely offered to all pregnant women in the UK between 28 and 38 weeks' gestation.<sup>16</sup> The percentage of pregnant women receiving the influenza vaccine, which is recommended for all pregnant women in the UK regardless of gestation during the influenza season, is only around 44.1%.<sup>4</sup> The reasons for these low rates are varied and much of the published work has focused on influenza vaccination in pregnancy.

A number of strategies to promote antenatal vaccine uptake have been tried, again particularly focusing on immunisation against influenza. In Stockport, Greater Manchester, UK, antenatal influenza vaccination uptake increased by almost 15% over 1 year through concentrated efforts using local media/social media, establishing links between midwifery and GP services, improving IT services, education of staff and good leadership.<sup>17</sup> Similarly, an Australian campaign based on raising health professionals' awareness of antenatal influenza vaccination through lectures and meetings, new patient information booklets and visual reminders on patient notes increased influenza vaccine uptake from 30% to 40%.<sup>18</sup> Our results also indicate that knowledge about the condition being prevented and support from healthcare professionals are key, and even brief interventions, such as the short paragraph about group B strep used in this survey, can significantly impact on the likelihood of vaccine uptake.

There is less information regarding attitudes towards antenatal group B strep vaccination, but this is a growing area of research. A recently published survey of 231 pregnant or recently delivered women in the USA showed remarkably similar results to this survey in that 79% of respondents indicated that they would be likely to have a group B strep vaccine in pregnancy.<sup>19</sup> Although 90% indicated that they were concerned about the safety of new antenatal vaccines, 95% of those surveyed responded that they generally followed their healthcare professional's recommendations. A Canadian qualitative study also found that a healthcare professional's recommendation would be a major factor in whether or not they would accept the vaccine, and concerns about safety were also raised.<sup>20</sup> Our findings suggest that while there are certain groups who may be more receptive to antenatal vaccination, there are others, such as women in their first pregnancy, who may require additional input to encourage vaccine uptake. These women may be more accepting if the antenatal vaccines are nationally recommended and may require extra time and provision of information to optimise discussion of vaccination options, particularly those focusing on the nature and seriousness of the conditions that are being vaccinated against.

There are a number of limitations to these findings that must be acknowledged. Respondents to the survey

**Figure 2** The important of advice from various sources of information when making decisions on antenatal vaccination. GP, general practitioner; NHS, National Health Service.



had volunteered to receive such questionnaires on multiple occasions and on various topics and therefore may be more open to research in general. There were few pregnant women within the sample and it is the views of these women, for whom the questions are not merely theoretical, which are key. However, the sample was relatively large and representative in terms of age, geography and social class, and therefore provides a useful framework on which to build future work. Of note, data on the women's ethnicity were not collected, which may be an important factor. The nature of an online survey also means that in-depth exploration of the decision-making process is not possible and more detail is needed on women's information requirements and how this should be delivered. Other details are lacking, such as how women self-defined being directly affected by the condition and why such a high proportion of women who did not know what the conditions were still rated them as serious. The rates reported here are higher than the invasive disease rates and some of those without children also considered themselves to have been directly affected by each of the conditions suggesting response bias. This may have been the result of confusion over what was being asked in this question or this group may contain relatives/friends of affected parents or women who have had a positive group B strep swab in pregnancy, rather than an affected child. However, this is consistent across all the conditions surveyed and it seems that this experience is sufficient to sway attitudes towards group B strep.

It is with these limitations in mind that further research on the acceptability of group B strep immunisation in pregnant women in the UK is being conducted using focus groups, interviews and questionnaires to specifically obtain the views of pregnant women and maternity healthcare professionals. If these findings support the data presented here, then, depending on the development of an effective and safe vaccine, immunisation

of pregnant women against group B strep could be the next major breakthrough in the prevention of neonatal sepsis and meningitis.

#### Author affiliations

<sup>1</sup>Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK

<sup>2</sup>Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St Georges, University of London, London, UK

<sup>3</sup>Group B Strep Support, Haywards Heath, West Sussex, UK

<sup>4</sup>Simpson Centre for Reproductive Health, Royal Infirmary, Edinburgh, UK

<sup>5</sup>Population, Policy and Practice Programme, UCL Institute of Child Health, London, UK

<sup>6</sup>Biostat Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

<sup>7</sup>Paediatric Infectious Diseases Research Group, Vaccine Institute, Institute for Infection and Immunity, St Georges, University of London, London, UK

**Twitter** Follow Jane Plumb at @JanePlumb

**Acknowledgements** The authors would like to thank the respondents to the online survey and E Di Antonio and Holly Wicks (ComRes) for assistance with survey preparation.

**Contributors** FM wrote the article which was reviewed by all authors. Data analysis was performed by FM, MDS and MV. All authors contributed to the design of the online survey.

**Funding** This survey was funded by a grant from Meningitis Now (formerly Meningitis UK), grant number 6000.

**Competing interests** PTH serves as a consultant to Novartis Vaccines regarding group B strep vaccine development. MDS has participated in advisory boards and/or been an investigator on clinical trials of vaccines sponsored by vaccine manufacturers including Novartis Vaccines, GlaxoSmithKline, Pfizer, Crucell and Sanofi Pasteur. Payment for these services was made to the University of Oxford Department of Paediatrics. MDS has had travel and accommodation expenses paid to attend conferences by Novartis Vaccines and GlaxoSmithKline. JP is the Chief Executive of Group B Strep Support, a charity which offers support and information to families affected by group B strep. She informs health professional about the prevention of group B strep infection and supports research into preventing these infections in newborn babies.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

- Okike IO, Ribeiro S, Ramsay ME, *et al.* Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004–11: an observational study. *Lancet Infect Dis* 2014; 14:301–7.
- Stoll BJ, Hansen NI, Sánchez PJ, *et al.* Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. *Pediatrics* 2011;127:817–26.
- Royal College of Obstetricians and Gynaecologists, The prevention of early-onset Group B streptococcal disease. 2012: Green Top guidelines No 36. 2nd Edition published 01 July 2012. <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg36/> (accessed 02 Feb 2016).
- Public Health England. *Influenza immunisation programme for England: data collection survey season 2014–2015*. 2015, PHE publications gateway number: 2015046.
- Zaman K, Roy E, Arifeen SE, *et al.* Effectiveness of maternal influenza immunization in mothers and infants. *N Engl J Med* 2008;359:1555–64.
- Amirthalingam G, Andrews N, Campbell H, *et al.* Effectiveness of maternal pertussis vaccination in England: an observational study. *Lancet* 2014;384:1521–8.
- Donegan K, King B, Bryan P. Safety of pertussis vaccination in pregnant women in UK: observational study. *BMJ* 2014;349:g4219.
- Public Health England. Prenatal pertussis immunisation programme 2014/2015: annual vaccine coverage report for England. 2015, PHE publications gateway number 2015282.
- McQuaid F, Jones C, Stevens Z, *et al.* Attitudes towards vaccination against group B streptococcus in pregnancy. *Arch Dis Child* 2014;99:700–1.
- Market Research Society. Occupational Groupings: a Job Dictionary. Sixth ed. 2006.
- Office of National Statistics. 2011 Census: quick statistics for England and Wales based on national identity, passports held and country of birth. 2013 (cited 5 February 2016). <http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-286348>
- Madhi SA, Leroux-Roels G, Koen A, *et al.* Safety and immunogenicity of an investigational maternal trivalent vaccine to prevent perinatal group B streptococcus (GBS) infection. ESPID conference; 30 May 2013.
- Slobod K. Novartis group B streptococcus vaccine programme. Meningitis Research Foundation Conference London, 2013.
- Vergnano S, Embleton N, Collinson A, *et al.* Missed opportunities for preventing group B streptococcus infection. *Arch Dis Child Fetal Neonatal Ed* 2010;95:F72–3.
- Public Health England, P.H., Pertussis vaccine coverage for pregnant women by month. 2013. <https://www.gov.uk/government/publications/pertussis-immunisation-in-pregnancy-vaccine-coverage-estimates-in-england-october-2013-to-march-2014/pertussis-vaccination-programme-for-pregnant-women-vaccine-coverage-estimates-in-england-october-2013-to-march-2014> (accessed 6 Feb 2016).
- Public Health England, Pertussis (whooping cough) immunisation for pregnant women. Updated March 2014. <http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/ImmunisationForPregnantWomen/>
- Baxter D. Approaches to the vaccination of pregnant women: experience from Stockport, UK, with prenatal influenza. *Hum Vaccin Immunother* 2013;9:1360–3.
- McCarthy EA, Pollock WE, Nolan T, *et al.* Improving influenza vaccination coverage in pregnancy in Melbourne 2010–2011. *Aust N Z J Obstet Gynaecol* 2012;52:334–41.
- Dempsey AF, Pyrzanowski J, Donnelly M, *et al.* Acceptability of a hypothetical group B strep vaccine among pregnant and recently delivered women. *Vaccine* 2014;32:2463–8.
- Patten S, Vollman AR, Manning SD, *et al.* Vaccination for group B streptococcus during pregnancy: attitudes and concerns of women and health care providers. *Soc Sci Med* 2006;63:347–58.